The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Diagnostics & Research
BGI Genomics Co., Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.65% CNY41.81
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17 138 mill |
| EPS: | 0.160 |
| P/E: | 261.31 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 409.91 mill |
| Avg Daily Volume: | 3.42 mill |
| RATING 2024-05-06 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 7.29x |
| Company: PE 261.31 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 9.11x |
| Company: PE 261.31 | industry: PE 28.70 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY27.24 (-34.85%) CNY-14.57 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 40.59 - 43.19 ( +/- 3.11%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY41.81 (1.65% ) |
| Volume | 4.21 mill |
| Avg. Vol. | 3.42 mill |
| % of Avg. Vol | 122.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 300676.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
300676.SZ
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.